The benefit of running clinical trials in Asia-Pacific for biotech companies
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
In association with Accelerating Clinical Trials
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on average each year between 2017…
Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the global COVID-19 crisis. According to…
Due to its geographic proximity with China, South Korea was one of the first locations hit with the Covid-19 viral infections. But the country has…
Business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech published a report summarising the main trends and developments…
The alliance of regional specialists can provide the best of all worlds: global coverage, regional specialisation and mid-sized CRO flexibility.…
Clinical development in oncology and immunotherapies has accelerated dramatically over the past few years. As of December 2019, over 6,000…
The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biotech companies wanting a fast…